172 related articles for article (PubMed ID: 16710819)
1. [New insights in the treatment of ANCA-associated systemic vasculitis].
Sinico RA; Sabadini E
G Ital Nefrol; 2006; 23(2):138-48. PubMed ID: 16710819
[TBL] [Abstract][Full Text] [Related]
2. [ANCA-associated vasculitis].
Sinico RA; Sabadini E; Boeri R; Radice A
G Ital Nefrol; 2002; 19(2):125-36. PubMed ID: 12195410
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
Feldmann M; Pusey CD
J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
[TBL] [Abstract][Full Text] [Related]
5. Current state of biologicals in the management of systemic vasculitis.
Lamprecht P; Till A; Steinmann J; Aries PM; Gross WL
Ann N Y Acad Sci; 2007 Sep; 1110():261-70. PubMed ID: 17911441
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the therapeutic strategies in ANCA-associated vasculitis--single centre experience with international randomized trials.
Vanková Z; Ríhová Z; Jancová E; Rysavá R; Merta M; Tesar V
Prague Med Rep; 2006; 107(2):199-212. PubMed ID: 17066740
[TBL] [Abstract][Full Text] [Related]
8. Systemic vasculitis: still a challenging disease.
Buhaescu I; Covic A; Levy J
Am J Kidney Dis; 2005 Aug; 46(2):173-85. PubMed ID: 16112036
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
[TBL] [Abstract][Full Text] [Related]
10. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Keogh KA; Wylam ME; Stone JH; Specks U
Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
[TBL] [Abstract][Full Text] [Related]
11. Review article: Progress of treatment in ANCA-associated vasculitis.
Jayne D
Nephrology (Carlton); 2009 Feb; 14(1):42-8. PubMed ID: 19335843
[TBL] [Abstract][Full Text] [Related]
12. Treatment of ANCA-associated systemic vasculitis.
Belmont HM
Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492
[TBL] [Abstract][Full Text] [Related]
13. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
Holle JU; Gross WL
J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of ANCA associated systemic necrotizing vasculitides].
Guillevin L
Bull Acad Natl Med; 2008; 192(6):1175-87; discussion 1188. PubMed ID: 19235481
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
Haubitz M; Schellong S; Göbel U; Schurek HJ; Schaumann D; Koch KM; Brunkhorst R
Arthritis Rheum; 1998 Oct; 41(10):1835-44. PubMed ID: 9778225
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis.
Little MA; Bhangal G; Smyth CL; Nakada MT; Cook HT; Nourshargh S; Pusey CD
J Am Soc Nephrol; 2006 Jan; 17(1):160-9. PubMed ID: 16306166
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ANCA-associated systemic small-vessel vasculitis.
Jayne D
APMIS Suppl; 2009 Jun; (127):3-9. PubMed ID: 19515133
[TBL] [Abstract][Full Text] [Related]
19. [New therapeutic strategies in ANCA-associated systemic vasculitis].
Ruiz FL; Bart PA
Rev Med Suisse; 2005 Jan; 1(1):19-23. PubMed ID: 15773192
[TBL] [Abstract][Full Text] [Related]
20. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides.
de Groot K; Jayne D
Clin Nephrol; 2005 Dec; 64(6):480-4. PubMed ID: 16370164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
